Assignee profile:

EpicentRx, Inc.

City:

La Jolla, California

Country:

United States

Published Applications:

31

Last publication date:

2026-02-05

Patent Grants:

22

Last grant date:

2025-05-06

Top Inventors for applications by EpicentRx, Inc.

These are the the leading inventors for applications assigned to EpicentRx, Inc.:

Recent patent applications by EpicentRx, Inc.

EpicentRx, Inc. based in La Jolla, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2026-02-05
US20260035346A1
Chemistry; metallurgy

CO-CRYSTALS OF 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHANONE AND METHODS

#2 | 2025-12-25
US20250388930A1
Chemistry; metallurgy

TUMOR SELECTIVE TATA-BOX AND CAAT-BOX MUTANTS

#3 | 2025-09-18
US20250288555A1
Human necessities

SYSTEMS AND METHODS TO IMPROVE EXERCISE TOLERANCE

#4 | 2025-05-22
US20250161548A1
Human necessities

MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS

#5 | 2025-05-01
US20250134858A1
Human necessities

COMPOSITIONS AND METHODS FOR TREATMENT OF NAFLD AND NASH AND RELATED DYSLIPIDEMIAS

#6 | 2025-03-27
US20250099666A1
Human necessities

MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS

#7 | 2025-03-06
US20250074967A1
Chemistry; metallurgy

IMMUNOMODULATORY FUSION PROTEINS

#8 | 2024-11-14
US20240374562A1
Human necessities

METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS

#9 | 2024-09-05 ✅ Patent 12,291,726 granted on 2025-05-06
US20240294883A1
Chemistry; metallurgy

A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter

#10 | 2024-05-09 ✅ Patent 12,357,608 granted on 2025-07-15
US20240148692A1
Human necessities

METHODS AND COMPOSITIONS UTILIZING RRx-001 COMBINATION THERAPY FOR RADIOPROTECTION

#11 | 2023-07-27
US20230235355A1
Chemistry; metallurgy

MONO- AND MULTI-VALENT SARS-COV- 2 ADENOVIRAL VECTOR VACCINES AND SARS-COV-2 IMMUNE GLOBULIN AND METHODS OF USE

#12 | 2023-07-27 ✅ Patent 12,357,607 granted on 2025-07-15
US20230233524A1
Human necessities

COMPOSITIONS AND METHODS FOR INTRAVENOUS ADMINISTRATION OF 2-BROMO-1-(3,3-DINITROAZETIDIN-1-YL)ETHANONE

#13 | 2022-04-28 ✅ Patent 12,280,123 granted on 2025-04-22
US20220125946A1
Human necessities

Recombinant adenoviruses carrying transgenes

#14 | 2022-02-24 ✅ Patent 11,701,351 granted on 2023-07-18
US20220054480A1
Human necessities

Treatment of gliomas using organonitro compound combination therapy

#15 | 2021-11-02 ✅ Patent 11,160,784 granted on 2021-11-02
US16456396
Human necessities

Treatment of brain metastases using organonitro compound combination therapy

#16 | 2021-08-12 ✅ Patent 12,048,793 granted on 2024-07-30
US20210244870A1
Human necessities

Medication infusion devices, systems, and methods

#17 | 2021-06-17 ✅ Patent 12,109,348 granted on 2024-10-08
US20210178050A1
Human necessities

Medication infusion devices, systems, and methods

#18 | 2021-05-13 ✅ Patent 12,054,530 granted on 2024-08-06
US20210139560A1
Chemistry; metallurgy

Immunomodulatory fusion proteins

#19 | 2021-01-21 ✅ Patent 12,295,976 granted on 2025-05-13
US20210015878A1
Human necessities

Personalized cancer vaccines

#20 | 2020-11-05 ✅ Patent 11,510,901 granted on 2022-11-29
US20200345690A1
Human necessities

Methods and compositions utilizing RRx-001 combination therapy for radioprotection

#21 | 2020-08-13 ✅ Patent 11,744,859 granted on 2023-09-05
US20200254016A1
Human necessities

Compositions and methods for parenteral administration of therapeutic agents

#22 | 2020-07-16 ✅ Patent 11,834,492 granted on 2023-12-05
US20200223901A1
Chemistry; metallurgy

Human IL-10 receptor alpha fusion proteins

#23 | 2020-05-21 ✅ Patent 11,008,287 granted on 2021-05-18
US20200157047A1
Chemistry; metallurgy

Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine

#24 | 2020-03-12 ✅ Patent 12,036,247 granted on 2024-07-16
US20200078415A1
Human necessities

Multiple transgene recombinant adenovirus

#25 | 2020-01-30 ✅ Patent 11,999,973 granted on 2024-06-04
US20200032223A1
Chemistry; metallurgy

Method for producing recombinant oncolytic adenovirus with modified E1a cancer-specific promoter

#26 | 2020-01-23 ✅ Patent 11,660,286 granted on 2023-05-30
US20200022952A1
Human necessities

Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products

#27 | 2019-10-10 ✅ Patent 11,576,895 granted on 2023-02-14
US20190307723A1
Human necessities

Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone

#28 | 2019-07-09 ✅ Patent 10,342,778 granted on 2019-07-09
US15298735
Human necessities

Treatment of brain metastases using organonitro compound combination therapy

#29 | 2019-05-02 ✅ Patent 10,543,208 granted on 2020-01-28
US20190125742A1
Human necessities

Treatment of gliomas using organonitro compound combination therapy

#30 | 2018-12-27 ✅ Patent 11,253,608 granted on 2022-02-22
US20180369404A1
Human necessities

Recombinant adenoviruses carrying transgenes

#31 | 2016-07-14 ✅ Patent 10,149,832 granted on 2018-12-11
US20160199346A1
Human necessities

Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof

Also check out EpicentRx, Inc.'s (La Jolla, United States) applicant profile with 32 patent applications submitted.

AssigneeID:

306510 ⎘